High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway-Reference-Cited by-同舟云学术

High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway

Published:2022-09-05 Issue:3 Volume:58 Page:264-268
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Leiva Rafael A.¹^ORCID,Bergersen Bente M.²,Finbråten Ane-Kristine²³,Sandvei Per Kristian⁴,Simonsen Øystein⁴,Rosseland Carola M.⁵,Hagen Karin⁶,Young Lital⁷,Roberts R. Scott⁸,Mikkelsen Yngve⁸,Singh Ravinder⁵,Lagging Martin⁹¹⁰^ORCID,Dalgard Olav¹¹¹²

Affiliation:

1. Department of Infectious Diseases, Haukeland University Hospital, Bergen, Norway

2. Department of Infectious Diseases, Oslo University Hospital, Ullevål, Norway

3. Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway

4. Department of Infectious Diseases, Østfold Hospital, Kalnes, Norway

5. MSD AS, Drammen, Norway

6. MSD AB, Stockholm, Sweden

7. MSD AG, Luzern, Switzerland

8. LINK Medical AS, Oslo, Norway

9. Department of Infectious Diseases/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

10. Department of Clinical Microbiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden

11. Department of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway

12. Institute for Clinical Medicine, University of Oslo, Oslo, Norway

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2022.2118555

Reference14 articles.

1. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C

2. Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

3. Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection – 16 weeks vs 12 weeks. 66th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA 2015. https://www.natap.org/2015/AASLD/AASLD_47.htm

4. EASL Recommendations on Treatment of Hepatitis C 2016

5. EASL Recommendations on Treatment of Hepatitis C 2018